Mechanisms of GOLPH3 associated with the progression of gastric cancer: A preliminary study

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Peng, Jinzhen ^a   Fang, Ye ^a   Tao, Yong ^a   Li, Keke ^a   Su, Ting ^a   Nong, Yuncui ^a   Xie, Fang ^a   Lai, Mingyu ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GOLGI PHOSPHOPROTEIN 3; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PHOSPHOPROTEIN; PROTEIN KINASE B; UNCLASSIFIED DRUG; EIF4EBP1 PROTEIN, HUMAN; GOLPH3 PROTEIN, HUMAN; MEMBRANE PROTEIN; MTOR PROTEIN, HUMAN; PROTEIN S6; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CARCINOGENESIS; CLINICAL FEATURE; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STOMACH CANCER; TUMOR INVASION; UPREGULATION; WESTERN BLOTTING; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHOSPHORYLATION; STOMACH TUMOR; TUMOR GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6; RNA, MESSENGER; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TOR SERINE-THREONINE KINASES; TRANSCRIPTION, GENETIC;

EID: 84907681957     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107362     Document Type: Article

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. (2011) Global cancer statistics. CA: A cancer journal for clinicians 61: 69-90.
2. Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, et al. (2009) Recent patterns in gastric cancer: A global overview. International Journal of Cancer 125: 666-673.
3. Snyder CM, Mardones GA, Ladinsky MS, Howell KE. (2006) GMx33 associates with the trans-Golgi matrix in a dynamic manner and sorts within tubules exiting the Golgi. Molecular biology of the cell 17: 511-524.
4. Wu CC, Taylor RS, Lane DR, Ladinsky MS, Weisz JA, et al. (2000) GMx33: A Novel Family of trans-Golgi Proteins Identified by Proteomics. Traffic 1: 963 -975.
5. Bell AW, Ward MA, Blackstock WP, Freeman HN, Choudhary JS, et al. (2001) Proteomics characterization of abundant Golgi membrane proteins. Journal of Biological Chemistry 276: 5152-5165.
6. Nakashima-Kamimura N, Asoh S, Ishibashi Y, Mukai Y, Shidara Y, et al. (2005) MIDAS/GPP34, a nuclear gene product, regulates total mitochondrial mass in response to mitochondrial dysfunction. Journal of cell science 118: 5357-5367.
7. Dippold HC, Ng MM, Farber-Katz SE, Lee SK, Kerr ML, et al. (2009) GOLPH3 bridges phosphatidylinositol-4-phosphate and actomyosin to stretch and shape the Golgi to promote budding. Cell 139: 337-351.
8. Scott KL, Kabbarah O, Liang MG, Ivanova E, Anagnostou V, et al. (2009) GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer. Nature 459: 1085-1090.
9. Abraham RT (2009) GOLPH3 links the Golgi network to mTOR signaling and human cancer. Pigment cell & melanoma research 22: 378-379.
10. Scott KL, Chin L (2010) Signaling From the Golgi: Mechanisms and Models for Golgi Phosphoprotein 3-Mediated Oncogenesis. Clinical Cancer Research 16: 2229-2234.
11. Washington K (2012) 7th edition of the AJCC cancer staging manual: Stomach. Annals of Surgical Oncology 17: 3077-3079.
12. Ma Y, Ren Y, Zhang X, Lin L, Liu Y, et al. (2014) High GOLPH3 expression is associated with a more aggressive behavior of epithelial ovarian carcinoma. Virchows Archiv 464: 443-452.
13. Xue Y, Wu G, Liao Y, Xiao G, Ma X, et al. (2014) GOLPH3 is a novel marker of poor prognosis and a potential therapeutic target in human renal cell carcinoma. British journal of cancer 110: 2250-2260.
14. Zhou J, Xu T, Qin R, Yan Y, Chen G, et al. (2012) Overexpression of Golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis. Journal of neuro-oncology 110: 195-203.
15. Wang JH, Chen XT, Wen ZS, Zheng M, Deng JM, et al. (2012) High expression of GOLPH3 in esophageal squamous cell carcinoma correlates with poor prognosis. PloS one 7: e45622.
16. L̄ H, Guo L, Chen SW, Zhao XH, Zhuang SM, et al. (2012) GOLPH3 overexpression correlates with tumor progression and poor prognosis in patients with clinically N0 oral tongue cancer. J Transl Med 10: 168.
17. Hu BS, Hu H, Zhu GY, Gu YL, Li JP (2013) Overexpression of GOLPH3 is associated with poor clinical outcome in gastric cancer. Tumor Biology 34: 515-520.
18. Guertin DA, Sabatini DM (2007) Defining the role of mTOR in cancer. Cancer cell 12: 9-22.
19. Fujiyoshi M, Ozaki M (2011) Molecular mechanisms of liver regeneration and protection for treatment of liver dysfunction and diseases. Journal of hepatobiliary-pancreatic sciences 18: 13-22.
20. Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes & development 18: 1926-1945.
21. Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103: 253-262.
22. Hresko RC, Mueckler M (2005) mTOR- RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. Journal of Biological Chemistry 280: 40406-40416.
23. Lazaridis G, Lambaki S, Karayannopoulou G, Eleftheraki AG, Papaspirou I, et al. (2014) Prognostic and predictive value of p-Akt, EGFR, and p-mTOR in early breast cancer. Strahlentherapie und Onkologie 190: 636-8, 640-5.
24. Sun CH, Chang YH, Pan CC (2011) Aivation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology 58: 1054 -1063.
25. No JH, Jeon YT, Park I, Kim YB, Kim JW, et al. (2011) Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer. Gynecologic oncology 121: 8-12.
26. Komori Y, Yada K, Ohta M, Uchida H, Iwashita Y, et al. (2014) Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors. Journal of hepato-biliary-pancreatic sciences 21: 288-295.
27. Pócza T, Sebestyén A, Turányi E, Krenács T, Márk A, et al. (2014) mTOR Pathway As a Potential Target In a Subset of Human Medulloblastoma. Pathology & Oncology Research. In press.
28. Karbowniczek M, Spittle CS, Morrison T, Wu H, Henske EP (2008) mTOR is activated in the majority of malignant melanomas. Journal of Investigative Dermatology 128: 980-987.
29. Slomovitz BM, Coleman RL (2012) The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. Clinical Cancer Research 18: 5856 -5864.
30. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, et al. (2008) Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135: 1972 -1983.